Nav: Home

Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class...

January 31, 2020

The cover for issue 68 of Oncotarget features Figure 4, "Gene expression changes to the TME demonstrate sequential development of innate and adaptive immune responses," by Leong, et al.

Intratumoral injection of SD-101 induces significant anti-tumor immunity in preclinical and clinical studies, especially when combined with PD-1 blockade.

Combination therapy generated CD8+ T cell dependent immunity leading to rejection of both non-injected and injected tumors and long-term survival, even in very large tumors.

Dr. Mary J. Janatpour from Dynavax Technologies, Inc., Emeryville, CA 94608,USA said, "It has long been appreciated by cancer researchers that the phenotypic heterogeneity and progressive evolution of malignant tumors minimizes the chance that any agent targeting a single molecular pathway could effectively cure advanced cancer."

The authors have previously demonstrated in mouse tumor models that employing the innate immune system to prime a T cell response, in combination with checkpoint blockade, results in deep and durable anti-tumor efficacy.

These high response rates were observed in both injected and non-injected tumor lesions and patients with PD-L1 negative tumors, indicating low levels of basal immune inflammation, responded as well as patients with PD-L1 positive tumors.

Intratumorally administered SD-101 exerts its priming activity and ultimate orchestration of a systemic anti-tumor T cell response through multiple mechanisms.

The production of interferon stimulates tumor cell killing by natural killer cells, with ensuing tumor antigen release, and induces chemokines that attract T cells back to the tumor bed.

Low-dose cyclophosphamide decreases Tregs. Additional impacted biological activities have been described, such as:
  • increased interferon production,
  • induction of immunogenic cell death,
  • increases in effector T cells, and
  • increases in functional NK cells,
...likely to be complementary to SD-101 activity by virtue of modulation of the TME. By administering SD-101 locally, rather than systemically, the researchers demonstrate that localized SD-101 injection combined with systemically administered low-dose cyclophosphamide confers an anti-tumor response at non-injected sites.

The Janatpour research Team concluded that, taken together, the intratumoral SD-101 plus low-dose CY combination may complement existing checkpoint blockade therapies in patients to improve efficacy in the clinic and extend the benefits of immunotherapy to more patients.
-end-
Full text - https://doi.org/10.18632/oncotarget.27322

Correspondence to - Mary J. Janatpour - mjanatpour@dynavax.com

Keywords - TLR9, SD-101, cyclophosphamide, immune therapy, innate immunity

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit http://www.oncotarget.com or connect with @Oncotarget

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
18009220957x105
MEDIA@IMPACTJOURNALS.COM

Impact Journals LLC

Related Tumor Articles:

Traces of immortality in tumor DNA
To gain an infinite lifespan, cancer cells need to maintain the ends of their chromosomes, known as telomeres.
Peering into the genome of brain tumor
Scientists at Osaka University have created a machine learning method for classifying the mutations of glioma brain tumors based on MR images alone.
Glutamine-blocking drug slows tumor growth and strengthens anti-tumor response
A compound developed by Johns Hopkins researchers that blocks glutamine metabolism can slow tumor growth, alter the tumor microenvironment and promote the production of durable and highly active anti-tumor T cells.
Cancer genes and the tumor milieu
In a recent study published in Cancer Research, researchers demonstrate the role of an oncogene in altering the immediate environment of tumors.
Mechanism of tumor metastasis and tumor-suppressive role of UDP-glucose revealed
Scientists from Dalian Institute of Chemical Physics (DICP) and Shanghai Institute of Biochemistry and Cell Biology (SIBCB) of the Chinese Academy of Sciences revealed that UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis.
The fluid that feeds tumor cells
MIT biologists have found that the nutrient composition of the interstitial fluid that normally surrounds pancreatic tumors is different from that of the culture medium normally used to grow cancer cells.
Insight into tumor-suppressive and tumor-promoting effects of cellular senescence
Wistar researchers have described a novel role of nicotinamide adenine dinucleotide (NAD+) metabolism in the ability of senescent cells to release tumor-promoting molecules.
A tumor cell population responsible for resistance to therapy and tumor relapse
Researchers at the Université libre de Bruxelles (ULB) uncover a tumor cell population responsible for resistance to therapy and tumor relapse in the most frequent human cancer.
New perspective on tumor genome evolution
An interdisciplinary team of scientists at the Centre for Genomic Regulation in Barcelona, Spain, deepens understanding of tumor genome evolution and suggests negative selection acting on cancer-essential genes plays a more important role than previously anticipated.
Cancer: Tumor transition states
Researchers at the Université libre de Bruxelles define for the first time the tumor transition states occurring during cancer progression and identify the tumor cell populations responsible for metastasis.
More Tumor News and Tumor Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Uncharted
There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 1: Numbers
In a recent Radiolab group huddle, with coronavirus unraveling around us, the team found themselves grappling with all the numbers connected to COVID-19. Our new found 6 foot bubbles of personal space. Three percent mortality rate (or 1, or 2, or 4). 7,000 cases (now, much much more). So in the wake of that meeting, we reflect on the onslaught of numbers - what they reveal, and what they hide.  Support Radiolab today at Radiolab.org/donate.